Table 3.

Subgroup comparison of review pathways

Subgroup	Standard	Priority	Notice of Compliance with conditions	Total
Small molecules	129	72	22	323
Biologics	73	45	8	126
Antineoplastic agents	34	26	21	81
Antivirals for systemic use	16	26	5	47
Immunosuppressants	22	13	1	36
All other 68 therapeutic groups	365	89	5	459

Small molecules vs biologics: Χ²=1.4402 (p=0.4867).

Antineoplastics vs antivirals vs immunosuppressants: Χ²=17.1978 (p=0.0018).

Antineoplastics+antivirals + immunosuppressants vs all other therapeutic groups: Χ²=97.4874 (p<0.00001).